AB ScienceXPAR:AB +1.86%59 Pretax Margin % is 549.01% as of Dec. 2025. GuruFocus rates XPAR:AB with a GF Score™ of 59/100 and a GF Value™ of €1.47 (Possible Value Trap). The stock has 11 warning signs investors should review. Among 952 Drug Manufacturers companies, AB Science ranks worse than 92.12% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. AB Science's Pre-Tax Income for the
six
months ended in Dec. 2025 was €3.62 Mil. AB Science's Revenue for the
six
months ended in Dec. 2025 was €0.66 Mil. Therefore, AB Science's pretax margin for the quarter that ended in Dec. 2025 was 549.01%.
The historical rank and industry rank for AB Science's Pretax Margin % or its related term are showing as below:
XPAR:AB'
s Pretax Margin % Range Over the Past 10 Years
Min: -1837.27 Med: -1309.83 Max: -132.71
Current: -132.71
XPAR:AB's Pretax Margin % is ranked worse than 92.12% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs XPAR:AB: -132.71
AB Science (XPAR:AB) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
AB Science Pretax Margin % Related Terms
AB Science Pretax Margin % Historical Data
* Premium members only.
The historical data trend for AB Science's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:AB vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AB Science's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AB Science Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AB Science's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where AB Science's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AB Science (XPAR:AB) has a Pretax Margin % of 549.01% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on AB Science and its competitors. According to the industry distribution chart, AB Science ranks #877 out of 952 companies in the Drug Manufacturers industry, placing it in the top 92.1%.
Is AB Science's Pretax Margin % too high?
AB Science's current Pretax Margin % is 549.01%. The Drug Manufacturers industry median Pretax Margin % is 7.30. AB Science's value of 549.01% is 7425.8% above this industry median. Based on the distribution chart, AB Science ranks #877 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AB Science has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AB Science's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AB Science ranks #877 out of 952 companies for Pretax Margin %. This places AB Science in the lower half of its industry. The industry median Pretax Margin % is 7.30. AB Science's value of 549.01% is 7425.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AB Science's current Pretax Margin % of 549.01% is 7425.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on AB Science and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AB Science's current Pretax Margin % is 549.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AB Science stock overvalued right now?
Based on GuruFocus' analysis, AB Science (XPAR:AB) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.90 — trading 38.9% below its estimated fair value. The current Pretax Margin % is 549.01% and 7425.8% above the Drug Manufacturers industry median of 7.30. AB Science's overall GF Score™ is 59/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For AB Science (XPAR:AB), the current Pretax Margin % is 549.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AB Science (XPAR:AB) Overvalued in 2026?
Based on GuruFocus' analysis, AB Science stock appears to be undervalued.
The current stock price of €0.90 is trading 38.9% below its estimated GF Value™ of €1.47.
GuruFocus considers AB Science to be Possible Value Trap.
Key valuation signals for XPAR:AB:
Pretax Margin %: 549.01%
GF Value™: €1.47 vs. price of €0.90 (38.9% below fair value)
Industry Position: 7425.8% above the Drug Manufacturers median (#877 of 952)
No single metric tells the full story. See the XPAR:AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
59GF Score
Get the complete analysis for XPAR:AB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:AB has been successfully added to your 
